Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs HubSpot Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.18 (market cap $8.04B), while HubSpot Inc trades at $215.96 (market cap $10.73B). The key difference: HubSpot Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| BIO | HUBS | |
|---|---|---|
Market Cap | $8.04B | $10.73B |
Sector | Health | Technology |
52-Week High | $339.75 | $560.90 |
52-Week Low | $241.71 | $170.39 |
Enterprise Value | $7.85B | $9.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
HubSpot (HUBS) trades at $217.59, up 4.87% with a bullish technical signal. The stock shows strong revenue growth, reaching $3.13B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with an 80.85% buy rating and a consensus price target of $273.53. Recent news highlights AI-driven expansion and customer growth, with the company hosting an Analyst Day in September 2026.
The outlook for HUBS is favorable due to robust fundamentals and AI integration, but risks include high valuation multiples and competitive pressures. Upside potential exists if earnings growth continues, though investors should monitor margin expansion and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
